Tag Archives: Winner

Interview with Kouris Kalligas, Winner of the Innovation Challenge in RESI Toronto

26 Apr

Kouris Kalligas

An interview with Kouris Kalligas, Founder & CEO, Therachat

– By Greg Mannix, VP of International Business Development, LSN

Greg Mannix

The San Francisco digital health startup Therachat came in 3rd at the RESI on MaRS Innovation Challenge in Toronto. Therachat is a mental health platform which simplifies homework in therapy for therapists & psychologists & their clients. Therapists & Psychologists can customize the homework experience for their clients via a simple web application and their clients can do their homework on an easy-to-use, HIPAA Compliant, mobile application. We believe that homework needed a simpler way and that’s what we have built!

CEO Kouris Kalligas registered early for the conference and put a lot of time and effort into his partnering strategy. When he was notified they would compete in the IC as finalists, he decided to bring along his colleague Sajid Reshamwala so they could maximize their presence at the conference.

Greg Mannix:  Kouris, how did you prepare for the RESI conference?

Kouris Kalligas:  I actually spent several solid days preparing our company profile on the RESI Partnering Platform and then reaching out to as many investors as possible who looked like a fit for us. The RESI Partnering is the best match-making platform I have seen! I could get a good idea of what each investor was looking for so I could decide who to request a meeting with.

GM: That’s great! How many meetings were you able to book?

KK: I was able to book 16 meetings! And what was really cool is that 10 investors who couldn’t meet with me at RESI gave me their emails through the messaging system, so I was able to contact them afterwards. I have been doing that since I got home. Fantastic!

GM: Wow! That’s impressive. Why do you think you got so much traction with investors?

KK:  I actually used 3 different messages and tried each one out on a handful of investors. I saw right away the one that was getting the most responses, so I focused on that message with the rest of investors I reached out to.

GM:  That is a great approach Kouris! I take it Sajid spent most of his day at the Therachat poster talking to people. How many Ad-Hoc meetings did Sajid have?

KK: I would guess about 20. Also, I sent every investor I spoke to check out our poster and invest their RESI cash in us! That’s so important:  Don’t be shy, just ask them to invest. I guess it was a good strategy!

GM: What would you say is the thing you liked most about RESI?

KK: That’s a tough one because we had a super productive day. But I would have to say it is the Partnering Platform. It really allowed me to identify the target investors I wanted to meet with and I could communicate with them through the messaging system. I probably sent out 200 or 300 messages!

Kouris Kalligas, Founder & CEO, Therachat

CEO & Founder of Therachat. I am passionate about technology & mental health. I have already one product under my belt called Addapp (check addapp.io) which I drove to 100k downloads and 10k daily active users. I believe that mental health is important and underserved. Technology can be a big enabler in the revolution that is coming to improving our mental health!

Greg Mannix, VP of International Business Development, LSN

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.

About Therachat

Therachat is a mental health platform which simplifies homework in therapy for therapists & psychologists & their clients. Therapists & Psychologists can customize the homework experience for their clients via a simple web application and their clients can do their homework on an easy-to-use, HIPAA Compliant, mobile application. We believe that homework needed a simpler way and that’s what we have built! Check www.therachat.io to find out more!

Interview with Yasaman, Winner of the Innovation Challenge in RESI Toronto

19 Apr

Yasaman Soudagar

An interview with Yasaman Soudagar, Founder & CEO, Neurescence

– By Greg Mannix, VP of International Business Development, LSN

Greg Mannix

Interview with Yasaman Soudagar: This year’s winner of the Innovation Challenge at RESI on MaRS was Neurescence, a Toronto-based company that has combined the power of novel optical imaging technology with advanced machine learning and quantum machine learning techniques for intelligent drug discovery for the diseases of the central nervous system.

CEO Yasaman Soudagar got a late start preparing for RESI, since she didn’t decide to attend until about 10 days before the conference, when she was informed that she would compete as a finalist in the Innovation Challenge. So I wanted to ask her how she managed to have such a successful conference, not to mention winning the Innovation Challenge, on such short notice.

Greg Mannix: Yasaman, you attended RESI alone, How did you get so many players to “invest” their RESI dollars in Neurescence and win the IC? Did you spend the whole day at your poster?

Yasaman Soudagar: Actually no! I moved around and looked for the places where the most people seemed to be hanging out, and I brought a tablet around so I could show them what our technology does, in a video of the actual imaging we do.

GM: Who did you target?

YS: One thing I really like about RESI is that all the investors are easy to spot because they have a red ribbon on their nametags. So it was really easy to approach investors and start a conversation.

GM: Was it difficult to get a conversation going, or did you find that most of the investors were approachable?

YS: I just went up to them and said “Hi, I am the founder of the coolest company on the planet”, which always at least drew a smile and a funny comment. Once I got their attention, then I had the chance to say “Here, let me show you”.

GM: Did you have very many one-on-one partnering meetings?

YS: I didn’t really have time to book a lot of meetings—I only had 2 scheduled, which I took at the poster. But I made a lot of great connections just by networking. In fact, I have already had follow-up meetings with investors I met at RESI.

GM: So all in all, it sounds like you had a good experience at RESI. What did you like most about the conference?

YS: It was a great event for me. I liked the density of relevant people and that it was easy to identify the investors. It was a great opportunity to network.

 

Yasaman Soudagar, Founder & CEO, Neurescence

Dr. Yasaman Soudagar holds a PhD in the field of experimental quantum optics, under the supervision of Dr. Nicolas Godbout at École Polytechnique de Montréal and Dr. Aephraim Steinberg at the University of Toronto. She then tenured an NSERC IRDF scholarship at Attodyne, a picosecond laser manufacturing company in Toronto. The exposure to the demands of a startup gave her the confidence to start her own, which is called Neurescence Inc. Soudagar has been building up Neurescence full time since Aug. 2015. Since then the product is developed and commercialized to the scientific research market.

Greg Mannix, VP of International Business Development, LSN

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.

 

About Neurescence

Neurescence has developed and commercialized a miniature microscope initially targeted to the Neurology research market. Our Quartet™ system gets implanted in multiple regions of the brain and spine and follows the activities of 100s of neurons in each region for months while the subject freely moves around. Our hardware-software suite is the only technology that allows establishing a causal connection between the effect of the treatment, such as a drug, on both the neuronal micro-circuitry and the disease phenotype. This extremely powerful approach takes the process of discovering and developing treatments from a trial and error method to an intelligent design.

RESI on MaRS Innovation Challenge – Check Out the Winners

12 Apr

By Chris Cummings, Senior Marketing Manager, LSN

On April 10, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Place: Neurescence

Neurescence has developed and commercialized a miniature microscope initially targeted to the neurology research market. Our Quartet™ system gets implanted in multiple regions of the brain and spine and follows the activities of 100s of neurons in each region for months while the subject freely moves around. Our hardware-software suite is the only technology that allows establishing a causal connection between the effect of the treatment, such as a drug, on both the neuronal micro-circuitry and the disease phenotype. This extremely powerful approach takes the process of discovering and developing treatments from a trial and error method to an intelligent design.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Yasaman Soudagar, Founder & CEO, Neurescence | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

Second Prize: Acorn Biolabs

People’s own cells have and will continue to become the foundation of the most important future biomedical therapeutics and regenerative medicine strategies. Aged cells, however, are highly mutated and deteriorated versions of our current cells. Precisely when people will need high-quality cells the most, their cells at that time will be at their worst. Acorn Biolabs has developed a novel non-invasive at-home kit to collect and viably transport cells. Acorn cryopreserves these cells as a way to ensure people will always have access to their own young therapeutically-capable cells. The value potential is immense; customer’s preserved cells are a life-long living resource, retrievable for direct use with advanced cell-based therapeutics, and analyzable for personal genomics, epigenomics, proteomics and beyond.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Steven ten Holder, Founder & COO, Acorn Biolabs | Drew Taylor, CEO, Acorn Biolabs | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

Third Prize: Therachat

Therachat is a mental health platform which simplifies homework in therapy for therapists & psychologists & their clients. Therapists & psychologists can customize the homework experience for their clients via a simple web application and their clients can do their homework on an easy-to-use, HIPAA compliant, mobile application. We believe that homework needed a simpler way and that’s what we have built! Check http://www.therachat.io to find out more!

Sajid Reshamwala, Director of Design, Therachat | Kouris Kalligas, CEO & Founder, Therachat | Dennis Ford, Founder & CEO, Life Science Nation | Ying Tam, Managing Director, Health Ventures, MaRS

If you missed out on the opportunity to compete in the RESI on MaRS Innovation Challenge, we’d be happy to take your application for our upcoming Boston event on June 4th.

Apply for RESI Boston Innovation Challenge Now!

 

 

RESI Boston 2017 Innovation Challenge – Winners Announced NYC Application is Now Open

28 Sep

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newOn Tuesday September 26th, RESI Boston was host to the largest RESI Innovation Challenge yet, with 40 companies competing for the “investment” votes of their fellow attendees. These innovative startups came from across the life science spectrum – develop ing novel products in biotech, medtech, diagnostics and healthcare IT, with the aim of addressing a wide range of different diseases. We hope that all will succeed in bringing their products to patients, but there could only be 3 prize winners. Without further ado, LSN would like to present the top three competitors:

First Place: Wellesley Pharmaceuticals

Nocturia, the frequent need to urinate at night, afflicts 2.3B people, causing insomnia, fatigue, depression, and lower quality of life. It leads to higher rates of heart disease, stroke, brain damage, and deadly falls, killing thousands daily. Wellesley’s Phase 2 trial ended 9/8/17. Results will be unblinded 10/2, but 50% of patients reported >25% nocturia reduction and 27% reported 40-96% benefits, with no side effects. 25% took placebo and 25% reported results averaging 0%. OAB drugs offer 10-15% benefits, bad side effects, and sell $2B/year! Licensing dozens of worldwide patents to big pharma comes next. We expect $10M upfront and 15% of revenue, while they take over all future costs, before launching our drug worldwide. Net margins should approach 95%.

Michael Quigley, VP of Investor Research, Life Science Nation | David Dill, CEO, Wellesley Pharmaceuticals | Dennis Ford, CEO, Life Science Nation

Second Place: Molecular Targeting Technologies

Molecular Targeting Technologies, Inc.’s (MTTI) TDURA is an imaging agent with a unique mechanism to “see” cell death. It is fast, sensitive and enables actionable tracking of cell damage, reducing toxicity,improving survival and minimizing healthcare costs. MTTI has demonstrated proof of efficacy in cardiotoxicity and oncology models. TDURA detected chemotherapy related cardiac dysfunction prior to existing technologies, detected tumor response to therapy as early as 1 day and distinguished responders from non-responders. TDURA is ready for clinical development. Phase II approval for the first indication is projected in 2022. Exit prior to phase III should deliver ≥$100 million value. MTTI has an experienced team, a strong IP and an innovative platform with multiple indications targeted to several unmet medical needs.

Michael Quigley, VP of Investor Research, Life Science Nation | Koon Yan “Chris” Pak, Co-Founder & CEO, Molecular Targeting Technologies, Inc. | Michael Silvon, Senior Vice President of Business Development, Molecular Targeting Technologies, Inc. | Dennis Ford, CEO, Life Science Nation

Third Place: RPS Diagnostics

RPS DIAGNOSTICS is developing FebriDx® for launch outside the USA in 2018. FebriDx is the first and only rapid, in-office test that uses a fingerstick blood sample to help differentiate viral from bacterial acute febrile respiratory infection. The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in 15 minutes, allowing for an effective treatment plan to be established during the patient’s initial office visit.

Michael Quigley, VP of Investor Research, Life Science Nation | Dennis Ford, CEO, Life Science Nation | Doug Lawrence, CEO, RPS Diagnostics

Thank you to all who competed in the RESI Boston Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Apply for RESI NYC Innovation Challenge Now!

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

Women CEOs Lead the Day at the RESI Innovation Challenge

27 Mar

By Maximilian Klietmann, VP of Marketing, LSN

Max Smile 2

RESI ended on Monday evening with over 400 attendees and over 660 partnering meetings. Additionally, 33 of the 150 biotech and medtech companies attending RESI were selected for the RESI Innovation Challenge, and competed for “RESI Cash” invested by conference attendees. Well, the winners are in:

  • The winners are global in nature, hailing from the US and Europe.
  • There was a tie for third place.
  • Women led the charge! Three of the four winning companies have women CEOs.

Scroll down to see the winning companies below (click the logos to visit company websites):

FIRST PLACE:

EMPIRIKO

Empiriko, based in Newton, MA, is addressing several of the challenges faced by scientists, clinicians and decision-makers responsible for taking drugs from concept to commercialization. The company’s Biomimiks™ solutions can help in predicting patient/drug interaction and can be used to optimize drug designs, and improve patient outcomes.

Pam Randhawa, Founder and CEO


SECOND PLACE:

BIOARRAY

BIOARRAY, based in Farmington, CT, is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

Marcia Fournier, CEO


THIRD PLACE (TIE):

STC logo

STC Biologics is a biotechnology company located in Cambridge MA focusing on development of biologic drugs. The company’s portfolio of drugs includes a MAb biosimilar for Oncology as well as a re-appropriated biologic drug for the treatment of Alzheimer’s.

Magdalena Leszczyniecka, President and CEO


THIRD PLACE (TIE):

Multineurons_logotype_300dpi

Multineurons, based in Switzerland, is developing medical devices for non-invasive and wireless brain-computer interface and brain diagnosis/therapy. The company’s products are based on a unique technology that evolved from more than a decade of R&D. 

Tasos Smeros, Founder & CEO

%d bloggers like this: